中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2010年
33期
21-24
,共4页
卵巢肿瘤%铂%抗肿瘤联合化疗方案%高压氧
卵巢腫瘤%鉑%抗腫瘤聯閤化療方案%高壓氧
란소종류%박%항종류연합화료방안%고압양
Ovarian neoplasms%Platinum%Antineoplastic combined chemotherapy protocols%Hyperbaric oxygenation
目的 探讨高压氧联合PC方案化疗对卵巢上皮性癌初治患者的疗效.方法 将58例卵巢上皮性癌术后患者采用随机数字表法分为研究组(30例)和对照组(28例),对照组给予环磷酰胺1000 mg/m2+顺铂75 mg/m2,21 d为1个疗程,至少6个疗程.研究组在高压氧2个标准大气压下暴露60 min,出舱25～30 min给予对照组方法化疗.比较两组的近期疗效和3年存活率、无进展生存时间以及不良反应等.结果 研究组近期总有效率、未控率、复发率、复发时间、3年存活率分别为83.3%(25/30)、6.7%(2/30)、33.3%(10/30)、(21.0±0.8)个月、43.3%(13/30),明显优于对照组的67.9%(19/28)、17.9%(5/28)、46.4%(13/28)、(18.0±0.6)个月、17.9%(5/28)(P＜0.05).研究组无进展生存时间和总生存时间明显长于对照组(P＜0.05),且不良反应发生率明显低于对照组(P＜0.05).结论 卵巢上皮性癌的辅助化疗中,高压氧联合PC方案疗效优于单纯PC方案,且高压氧能明显减少PC方案不良反应.
目的 探討高壓氧聯閤PC方案化療對卵巢上皮性癌初治患者的療效.方法 將58例卵巢上皮性癌術後患者採用隨機數字錶法分為研究組(30例)和對照組(28例),對照組給予環燐酰胺1000 mg/m2+順鉑75 mg/m2,21 d為1箇療程,至少6箇療程.研究組在高壓氧2箇標準大氣壓下暴露60 min,齣艙25～30 min給予對照組方法化療.比較兩組的近期療效和3年存活率、無進展生存時間以及不良反應等.結果 研究組近期總有效率、未控率、複髮率、複髮時間、3年存活率分彆為83.3%(25/30)、6.7%(2/30)、33.3%(10/30)、(21.0±0.8)箇月、43.3%(13/30),明顯優于對照組的67.9%(19/28)、17.9%(5/28)、46.4%(13/28)、(18.0±0.6)箇月、17.9%(5/28)(P＜0.05).研究組無進展生存時間和總生存時間明顯長于對照組(P＜0.05),且不良反應髮生率明顯低于對照組(P＜0.05).結論 卵巢上皮性癌的輔助化療中,高壓氧聯閤PC方案療效優于單純PC方案,且高壓氧能明顯減少PC方案不良反應.
목적 탐토고압양연합PC방안화료대란소상피성암초치환자적료효.방법 장58례란소상피성암술후환자채용수궤수자표법분위연구조(30례)화대조조(28례),대조조급여배린선알1000 mg/m2+순박75 mg/m2,21 d위1개료정,지소6개료정.연구조재고압양2개표준대기압하폭로60 min,출창25～30 min급여대조조방법화료.비교량조적근기료효화3년존활솔、무진전생존시간이급불량반응등.결과 연구조근기총유효솔、미공솔、복발솔、복발시간、3년존활솔분별위83.3%(25/30)、6.7%(2/30)、33.3%(10/30)、(21.0±0.8)개월、43.3%(13/30),명현우우대조조적67.9%(19/28)、17.9%(5/28)、46.4%(13/28)、(18.0±0.6)개월、17.9%(5/28)(P＜0.05).연구조무진전생존시간화총생존시간명현장우대조조(P＜0.05),차불량반응발생솔명현저우대조조(P＜0.05).결론 란소상피성암적보조화료중,고압양연합PC방안료효우우단순PC방안,차고압양능명현감소PC방안불량반응.
Objective To discuss the therapentic efficacy of hyperbaric oxygen combined with PC program in newly diagnosed epithelial ovarian cancer patients. Methods Fifty-eight patients with epithelial ovarian cancer were divided into two groups by random digits table: HBO group(30 cases) and PC group(28cases). HBO group were exposed to hyperbaric oxygen of 2 standard atmospheric pressure 60 min, then given chemotherapy 25-30 min after extravehicular: cyclophosphamide 1000 mg/m2 + cisplatin 75 mg/m2.PC group with the same regimen without hyperbaric oxygen therapy were analyzed. The two groups were compared in the efficacy and 3-year survival rate, progression-free survival and adverse reactions. Results The total effective rate, not controlled rate, recurrence rate,recurrence time, 3-year survival rate in HBO group [83.3%(25/30),6.7%(2/30),33.3%(10/30), (21.0 ± 0.8) months,43.3%(13/30)] were better than those in PC group [67.9% (19/28), 17.9% (5/28), 46.4% (13/28), (18.0 ± 0.6) months, 17.9% (5/28)] (P ＜0.05), progression-free survival and overall survival time in HBO group were longer than those in PC group (P ＜0.05) and adverse reactions rate in HBO group was lower than that in PC group (P ＜0.05).Conclusions The hyperbaric oxygen combined with PC programs are better than PC programs in advanced epithelial ovarian cancer chemotherapy response rate, progression-free survival time and 3-year survival rates in ovarian cancer adjuvant chemotherapy. HBO can significantly reduce the PC's hematological toxicity and toxicity of the digestive system.
